SavedAdd your journal

Journals / Türk Biyokimya Dergisi / 2021 / Cilt: 46 - Sayı: 4

Immature platelet fraction: is a novel early predictive marker for disease severity in patients with Covid-19 pneumonia?

İmmatür Platelet Fraksiyonu: Covid-19 Pnömonisi Olan Hastalarda Hastalık Şiddeti İçin Yeni Bir Erken Prediktif Belirteç olabilir mi?

Tuncay DAĞEL
Mahir KAPMAZ
Alparslan KILIÇ
Arzu BAYGÜL
Zeynep ATAM TAŞDEMİR
Timur Selçuk AKPINAR
Said İNCİR
Kerim Erhan PALOĞLU
Zeynep KÖMEŞLİ
Kayra SOMAY
Hatice KANT
Ayşe OKAN
Suda TEKİN
Pages
359–366
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Given laboratory parameters, the median IPF% was significantly higher in the severe group (11.9 vs. 3.9%, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: In many diseases, immature platelet fraction (IPF%) is related to coagulopathy and poor outcome.
📊
Key Findings & Data:This study aimed to investigate the predictive value of IPF% for the severity of pneumonia in patients with Coronavirus Disease 2019 (COVID-19).
💡
Conclusion & Impact:Results: Given laboratory parameters, the median IPF% was significantly higher in the severe group (11.9 vs. 3.9%, p
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: In many diseases, immature platelet fraction (IPF%) is related to coagulopathy and poor outcome. This study aimed to investigate the predictive value of IPF% for the severity of pneumonia in patients with Coronavirus Disease 2019 (COVID-19). Methods: A total of 154 patients with COVID‐19 infections were included. The patients were divided into two groups according to the severity of pneumonia (severe and non severe) regarding their oxygen demand. Results: Given laboratory parameters, the median IPF% was significantly higher in the severe group (11.9 vs. 3.9%, p

Özet

Amaç: Pek çok hastalıkta, immatür platelet fraksiyonu (%İPF), koagülopati ve kötü sonuçla ilişkilidir. Bu çalışma, Coronavirus Hastalığı 2019 (COVID-19) olan hastalarda pnömoni şiddeti için %İPF’nin prediktif değerini araştır mayı amaçladı. Yöntem: COVID-19 enfeksiyonu olan toplam 154 hasta dahil edildi. Hastalar, oksijen ihtiyaçları göz önüne alına rak pnömoni şiddetine göre (ağır ve ağır olmayan) iki gruba ayrıldı. Bulgular: Laboratuvar parametrelerine bakıldığında, med yan İPF yüzdesi ağır grupta anlamlı olarak daha yüksekti (% 11.9′a karşı %3.9, p

🔖

Cite This Article

DAĞEL, T., KAPMAZ, M., KILIÇ, A., BAYGÜL, A., TAŞDEMİR, Z. A., AKPINAR, T. S., İNCİR, S., PALOĞLU, K. E., KÖMEŞLİ, Z., SOMAY, K., KANT, H., OKAN, A., TEKİN, S. (2022). Immature platelet fraction: is a novel early predictive marker for disease severity in patients with Covid-19 pneumonia?. Türk Biyokimya Dergisi, Cilt: 46 - Sayı: 4, 359–366. https://ajindex.com/articles/620680

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta 2020;506:145–8
  2. World Health Organization. WHO coronavirus disease (COVID-19) dashboard. (Accessed 11 March 2021)
  3. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemostasis 2020;18:1421–4
  4. White D, MacDonald S, Edwards T, Bridgeman C, Hayman M, Sharp M, et al. Evaluation of COVID-19 coagulopathy; laboratory characterization using thrombin generation and nonconventional haemostasis assays. Int J Lab Hematol 2021;43:123–30
  5. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemostasis 2020;18:844–7
  6. Orf K, Rogosic S, Dexter D, Ancliff P, Badle S, Brierley J, et al. Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID-19. Br J Haematol 2020; 190:e274–6
  7. Muronoi T, Koyama K, Nunomiya S, Lefor AK, Wada M, Koinuma T, et al. Immature platelet fraction predicts coagulopathy-related platelet consumption and mortality in patients with sepsis. Thromb Res 2016;144:169–75
  8. Lev EI. Immature platelets. Circulation 2016;134:987–8
  9. Park SH, Ha SO, Cho YU, Park CJ, Jang S, Hong SB. Immature platelet fraction in septic patients: clinical relevance of immature platelet fraction is limited to the sensitive and accurate discrimination of septic patients from non-septic patients, not to the discrimination of sepsis severity. Ann Lab Med 2016;36:1–8
  10. Briggs C, Kunka S, Hart D, Oguni S, Machin SJ. Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol 2004;126:93–9
  11. De Blasi RA, Cardelli P, Costante A, Sandri M, Mercieri M, Arcioni R. Immature platelet fraction in predicting sepsis in critically ill patients. Intensive Care Med 2013;39:636–43
  12. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20
  13. Sayan İ, Altınay M, Çınar AS, Türk HŞ, Peker N, Şahin K, et al. Impact of HFNC application on mortality and intensive care length of stay in acute respiratory failure secondary to COVID-19 pneumonia. Heart Lung 2021;50:425–9
  14. Yesildal F, Isman FK. High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical